Lateral Flow Immunoassay (LFIA) Based Rapid Test Market

Lfia Based Rapid Test Market Outlook - 2026

The global LFIA based rapid test market was valued at $4,725 million in 2018, and is projected to reach $8,494 million by 2026, registering a CAGR of 7.6% from 2019 to 2026

Lateral flow tests, or lateral flow immunochromatographic assays, are simple cellulose-based medical devices used to detect the presence of a target analyte in sample without use of specialized equipment where preliminary screening tests need to be conducted.  

LFIA based rapid test market is expected to experience significant market growth during the forecast period as these tests are easy to perform, quick, and provide specific results; hence, are used in settings with limited resources. In addition, increased promotional activities by manufacturers encourage the usage these tests, rise in awareness regarding early diagnosis of disease, surge in initiatives by the government agencies, and increase in incidence of infectious diseases further supports the market growth. However, stringent government regulations for the approval of rapid tests and recall of several products due to false results are expected to impede the LFIA based rapid test market growth.  

Lfia Based Rapid Test Market Segmentation  

The global rapid tests market is segmented into application, technique, end user, and region. The applications covered in the study include, infectious disease, pregnancy & fertility, toxicology, and others. Depending on techniques, the market is classified into competitive assay, sandwich assay, and multiplex detection assay. The infectious disease segment is further categorized into influenza, mosquito-borne diseases, HIV, hepatitis, and others. In addition, Dengue, chikungunya, malaria, and others are covered under mosquito-borne diseases. According to end user, the market is segmented into hospital & clinic, diagnostic laboratory, home care, and others. By region, the lateral flow immunoassay based rapid test market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, Philippines, Vietnam, Malaysia, Thailand, Singapore, Indonesia, Myanmar, Sri Lanka, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Segment review 

The applications covered in the study include infectious disease, pregnancy & fertility, toxicology, and others. The infectious disease segment is further divided into influenza, mosquito-borne diseases, HIV, hepatitis, and others. Dengue, chikungunya, malaria, and others are covered under mosquito-borne diseases. 

Infectious disease segment is anticipated to show significant growth during the forecast period, owing to increase in adoption of LFIA based rapid test for preliminary screening; rise in initiatives by government & private organization for diagnosis of infectious diseases; and surge in incidence of infections such as mosquito born disease, hepatitis, and others. 

Moreover, easy availability of cost-efficient products, rise in promotion activities by the key players for LFIA based rapid test, and increase in use of LFIA based rapid test among the general population fuel the growth of this segment.  

At present, home care is a major revenue contributor, and is anticipated to dominate the lateral flow immunoassay based rapid test market during the forecast period. This is attributed to availability of cost-efficient products, increase in promotional activities by manufacturers for usage LFIA based rapid tests kits, and rise in awareness about home care rapid tests. On the other hand, the hospitals & clinics segment is anticipated to grow at the highest rate, majorly due to increase in incidence of different diseases such as HIV, infectious disease, cancer, and others, and rise in adoption of convenient rapid tests kits in hospitals. 

Snapshot of Asia-Pacific LFIA based rapid test market  

Region wise, Asia-Pacific presents lucrative opportunities for the key players operating in the LFIA based rapid test market, owing to presence of high population base, increase in awareness about LFIA based rapid test, development in healthcare infrastructure, and increase in demand for LFIA based rapid test. However, insurance companies do not cover the test expenses, which is expected to hamper the lateral flow immunoassay based rapid test market growth in Asia-Pacific.  

The key players profiled in this report include Abbott Laboratories (Alere Inc.), Becton, Dickinson and Company, Bio-rad Laboratories, Inc., Danaher Corporation (Cepheid, Inc.), Hologic, Inc., Quidel Corporation, F. Hoffmann-La Roche AG (Roche Diagnostics), Biomerieux SA, Qiagen N.V., and Thermo Fisher Scientific. 

Key Benefits for Lfia Based Rapid Test Market :

• The study provides an in-depth analysis of the LFIA based rapid test market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers LFIA based rapid test market analysis from 2019 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
• A comprehensive analysis of all the geographical regions is provided to determine the prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global LFIA based rapid test market growth.

 Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Report Highlights